Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

被引：2
|
作者：
Luster, Markus [1 ]
Schlumberger, Martin [2 ]
Pacini, Furio [3 ]
机构：
[1] Univ Ulm, Dept Nucl Med, D-89081 Ulm, Germany
[2] Inst Gustave Roussy, Dept Nucl Med & Endocrine Oncol, F-94805 Villejuif, France
[3] Univ Siena, Sect Endocrinol & Metab, Dept Internal Med, I-53100 Siena, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷 / 02期
关键词：
HORMONE WITHDRAWAL; RADIOIODINE THERAPY; MANAGEMENT; CARCINOMA; DOSIMETRY; ABLATION;
D O I：
10.1007/s00259-008-1013-9
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：329 / 330
页数：2
相关论文
共 50 条
  • [11] Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer
    Guo, Yiling
    Zhang, Yingnan
    Chen, Zuowei
    Xin, Zhenfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (05) : 1847 - 1850
  • [12] Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
    Ha, Jeonghoon
    Kim, Min Hee
    Jo, Kwanhoon
    Lim, Yejee
    Bae, Ja Seong
    Lee, Sohee
    Kang, Moo Il
    Cha, Bong Yun
    Lim, Dong Jun
    MEDICINE, 2017, 96 (29)
  • [13] Recombinant Human TSH Versus Thyroid Hormone Withdrawal
    Verburg, Frederik A.
    Dietlein, Markus
    Freudenberg, Lutz
    Leboulleux, Sophie
    Pitoia, Fabian
    Reiners, Christoph
    Stokkel, Marcel
    Luster, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (11) : 1815 - 1816
  • [14] Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer
    Podoba, J.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2010, 111 (01): : 38 - 40
  • [15] THE ROLE OF RECOMBINANT HUMAN THYROTROPIN FOR DIAGNOSTIC MONITORING OF PATIENTS WITH DIFFERENTIATED THYROID CANCER
    Sherman, Steven I.
    ENDOCRINE PRACTICE, 2013, 19 (01) : 157 - 161
  • [16] The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
    Zygmunt, Arkadiusz
    Krawczyk-Rusiecka, Kinga
    Skowronska-Jozwiak, Elzbieta
    Wojciechowska-Durczynska, Katarzyna
    Glowacka, Ewa
    Adamczewski, Zbigniew
    Lewinski, Andrzej
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [17] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Pitoia, Fabian
    Abelleira, Erika
    Cross, Graciela
    ENDOCRINE, 2017, 55 (01) : 209 - 217
  • [18] Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation
    Vrachimis, A.
    Schober, O.
    Riemann, B.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2012, 51 (03): : 67 - 72
  • [19] Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium
    Barbaro, Daniele
    Grosso, Mariano
    Boni, Giuseppe
    Lapi, Paola
    Pasquini, Cristina
    Orsini, Paola
    Turco, Anna
    Meucci, Giuseppe
    Marzola, Maria Cristina
    Berti, Piero
    Miccoli, Paolo
    Mariani, Giuliano
    Rubello, Domenico
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (02) : 242 - 249
  • [20] POTENTIAL USE OF RECOMBINANT HUMAN THYROTROPIN IN THE TREATMENT OF DISTANT METASTASES IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
    Klubo-Gwiezdzinska, Joanna
    Burman, Kenneth D.
    Van Nostrand, Douglas
    Mete, Mihriye
    Jonklaas, Jacqueline
    Wartofsky, Leonard
    ENDOCRINE PRACTICE, 2013, 19 (01) : 139 - 148
12345